analogs to trastuzumab, deruxtecan and trastuzumab emtansin, respectively. In red monkey and human plasma, DB-1303 demonstrated high drug to antibody ratio and outstanding plasma stability. Two points to that. So first is actually the volumes, while we're not disclosing volumes in the first quarter, we were shipping to quite a broad range of countries in the first quarter, over 70 countries we mentioned. There's still some carryover there to pandemic contracts. And so, as I mentioned in the prepared remarks ...

The increase of intangible assets by €158.9 million during the three months ended March 31, 2023 is mainly due to licenses acquired that meet the definition of identifiable assets in the amount of €158.0 million in connection with the License and Collaboration Agreements entered into between us and Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, in March 2023. Set out below is an overview of financial assets, other than cash and cash equivalents, held as of March 31, 2023 and December Derivatives not ...

BioNTech SE (NASDAQ:BNTX) Q4 2022 Results Conference Call March 27, 2023 8:00 AM ET Company Participants Michael Horowicz - IR and Strategy Ugur Sahin - CEO and Co-Founder Özlem Türeci - Chief Medical Officer and Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Matthew Harrison - Morgan Stanley Yaron Werber - Cowen Jessica Fye - JP Morgan Michael Horowicz Good morning and afternoon. Thank you ...

Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1* — The Nasdaq Stock Market LLC* FORM 20-F Securities registered or to be registered, pursuant to Section 12(b) of the Act Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Page GENERAL INFORMATION 3 CAUTIONARY STATEMENT RE ...

1 1 "We made significant progress in 2022 by advancing our pipeline and launching the world's first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine. In addition, multiple new modalities achieved encouraging clinical data and we progressed nine new programs into clinical trials," said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. "As we look to 2023 and beyond, we plan to continue investing in our transformation with a focus on building commercial capabilities in oncology and working towards re ...

BioNTech SE (NASDAQ:BNTX) JP Morgan Annual Healthcare Conference January 10, 2023 12:45 PM ET Company Participants Ugur Sahin - Chief Executive Officer & Co-Founder Ryan Richardson - Chief Strategy Officer Conference Call Participants Jessica Fye - JPMorgan Jessica Fye Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with BioNTech. [Operator Instructions] So with that, let me turn it over to BioNTech ...

BioNTech SE (NASDAQ:BNTX) Q3 2022 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations & Strategy Ugur Sahin - Chief Executive Officer & Co-Founder Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Jessica Fye - JPMorgan Daina Graybosch - SVB Leerink Ellie Merle - UBS S ...

Exhibit 99.1 BIONTECH BioNTech SE Quarterly Report of BioNTech SE for the Three And Nine Months Ended September 30, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income 4 Interim Condensed Consolidated Statements of Financial Position 5 Interim Condensed Consolidated Statements of Changes in Stockholders' Equity 6 Interim Condensed Consolidated Statements ...

BioNTech SE (NASDAQ:BNTX) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations and Strategy Ugur Sahin - Chief Executive Officer and Co-Founder Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Zhiqiang Shu - Berenberg Operator ...

Exhibit 99.1 BIONTECH BioNTech SE Quarterly Report BioNTech SE for the Three And Six Months Ended June 30, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 3 Interim Condensed Consolidated Statements of Comprehensive Income 4 Interim Condensed Consolidated Statements of Financial Position 5 Interim Condensed Consolidated Statements of Changes in Stockholders' Equity 6 Interim Condensed Consolidated Statements of Cash ...